Clinical Trial Search

Primary: Change From Baseline in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Score — 0.0; -3.7; -3.4; -3.9 score on a scale…

Primary: Eye Contact/Gaze During 10 Minute Social Challenge Task — 15.4; 20.9; 17.0 eye contact/gaze events per 10 minutes

Primary: 2-year Overall Survival Rate — 31 percentage of participants

Primary: Change From Baseline in Vaginal Bleeding — -83.5; -36.0; -63.5; -39.5 mL

Primary: Response Rate [Complete Response (CR) and Partial Response (PR)] — 0; 0; 0; 1 participants

Primary: Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the Treatment Period — 48.1; 48.9 percentage of participants — p=0.954

Primary: Progression-free Survival — 11.6 Months

Primary: Response (Complete Response [CR] + Partial Response [PR]) — 6 participants

Primary: Change in Platelet Activity, Measured in Seconds on PFA-EPI Assay, From Pre to Post-treatment — 68 seconds — p=0.014

Primary: Area Under the Curve (AUC) of the Pain Scores. — 6843; 8832; 9998; 7290 mm*minutes

Primary: Pupil Diameter (mm) During Surgery — 8.0; 8.0; 8.1; 9.0 mm — p=0.0000

Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants

Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -11.5; -11.3; -12.1; -10.3 units on a scale

Primary: Overall Survival (OS) — 5.3 months

Primary: Core Study: Change From Baseline in Myocardial T2* (Magnetic Resonance T2-star (T2*) Technique for the Measurement of Tissue Iron) After 12 Months Treatment — 1.12; 1.07…